Pharming Group Shares Surge 4.69% Midday Following Better-than-Expected 2025 Results
Pharming Group's stock marked a significant increase of 4.69% at midday on Thursday, January 8, reaching 1.54 euros, driven by the release of preliminary 2025 results that surpassed the group's revised targets. With over 3% of the capital traded since the opening, the stock continues its rebound from recent weeks and confirms its long-term upward trend.
Strong Financial Performance Exceeds Expectations
Pharming Group announced this Thursday a preliminary unaudited revenue of $376 million for the fiscal year 2025, exceeding the revised range of $365 to $375 million announced in November. This performance represents an approximate 27% increase from 2024, driven by the ongoing growth of RUCONEST and increasing demand for Joenja, primarily fueled by adoption in the United States and supported by ongoing geographic expansion. Operational expenses are expected to fall within the previously communicated range of $304 to $308 million, demonstrating cost control. This announcement, made in the morning, explains the strong market reaction, with investors applauding superior business execution in an increasingly competitive environment. Technically, the stock is now significantly above its 50-day moving average of 1.38 euros, confirming a short-term bullish trend. The RSI indicator at 56 points remains in a neutral zone, suggesting that there is still room for progress before reaching overbought levels. Crossing the resistance threshold of 1.51 euros, tested during the session, would be an additional technical signal for the continuation of the rise.
Impressive Weekly and Quarterly Gains
At midday, Pharming Group shows a weekly gain of 8.07% and a quarterly increase of 24.17%, reflecting a renewed interest from investors since the fall. On an annual basis, the performance reaches 65.97%, driven by the ramp-up of Joenja in the American market and an expanded patient base. The sustained trading volume this Thursday, representing 3.37% of the capital, indicates marked interest from traders following the release of the preliminary results. The group also announced a virtual investor day on February 3, 2026, during which financial forecasts for 2026 will be presented along with a comprehensive update on the development portfolio. From a fundamental viewpoint, the consensus of analysts on November 11, 2025, indicated a three-month average price target of 2.41 euros, representing a potential upside of 65.89% from the last price, with dominant buy recommendations. These targets could be revised upwards in the coming weeks in light of the final results to be published on March 12 and the new commercial prospects expected during the investor day.
Leadership and Clinical Pipeline Progress
Fabrice Chouraqui, CEO of Pharming, highlighted that RUCONEST has continued to grow in an increasingly competitive environment, while the adoption of Joenja has accelerated with rising demand from American patients and international expansion. The clinical pipeline remains active with leniolisib in Phase II for primary immunodeficiencies with immune dysregulation and KL1333 in a pivotal study called FALCON for mitochondrial diseases linked to mitochondrial DNA. The technical setup remains favorable, with the stock largely above its long-term moving averages, particularly the MM200 at 1.23 euros, indicating a solidly bullish underlying trend. The Stochastic indicator positioned for buying and a positive Chaikin money flow of 0.11 confirm net capital inflows into the stock. With definitive results expected in early March and an investor day scheduled in early February, the calendar for the coming weeks is packed with catalysts likely to fuel the current momentum of the stock.
